MHRA advice for all AEDs and random info Flashcards
risk of suicidal thoughts and behaviour
all antiepileptic drugs may be associated with a small increased risk of suicidal thoughts and behaviour; symptoms may occur as early as 1 week after starting treatment.
seek medical advice if any mood changes, distressing thoughts, or feelings about suicide or self-harming develop, and that the patient should be referred for appropriate treatment if necessary.
Patients should also be advised not to stop or switch antiepileptic treatment and to seek advice from a healthcare professional if concerned.
a patient has suicidal thoughts. you look at their PMR and they take pregabalin, not for epilepsy. what do you do
All AEDs have the potential to cause suicidal thoughts and behaviour
Refer to GP
Do not stop treatment
Switching between different manufacture products
3P and 1C must be maintained on specific brand
Carbamazepine, phenobarbital, phenytoin, primidone.
valproate - full pack dispensing - is it for females only?
Pharmacists are advised that all patients (male and female) must receive their valproate medicines in the manufacturer’s original full pack (i.e. original pack dispensing) and the amount dispensed must be as close as possible to the amount stated on the prescription (NHS or private)
latest data on valproate - who can it be started in & is it just for epilepsy indications
- do not start in new pt aged under 55 unless 2 specialists independently agree that there is no other effective or tolerated treatment, or there are compelling aeons why the reproductive risks do not apply
- at next annual specialist review, females of CBP to be reviewed using new risk acknowledgement form which will include the need for a 2nd specialist signature if pt is to continue
- subsequent annual reviews with ONE specialist should be carried out
- FOR ALL INDICATIONS not just epilepsy
MHRA - valproate and vitamin D
The MHRA advises consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.
topiramate - latest MHRA advice re PPP
- teratogenic: congenital malformations, low birth weight, potential increased risk intellectual disability, ASD and ADHD
- do not use in FoCBP unless PPP
-use in pregnancy CI for migraine prophylaxis - only use in pregnancy for epilepsy if no suitable alt
Cannabidiol epidyolex oral solution - what CD class is it
CD 5
What does topiramate PPP consist of
- all new and existing FoCBP on topiramate to be explained conditions of PPP, provided patient guide, complete and sign Risk Awareness Form (at initiation and each annual review)
- Pharmacists: ensure whole pack dispensing wherever possible; all packs dispensed to FoCBP should have warning symbol either on carton or via sticker
- Pharmacists to alos provide Patient Card and check if patient using highly effective contraception; if not refer to GP
Which AED is associated with visual field defects
Vigabatrin
carry out testing before treatment and at 6 month intervals
Patient with absence seizures is on first line treatment. You warn them of blood disorders and to seek medical attention if symptoms like fever, mouth ulcers, bruising, bleeding develop. What drug?
ethosuximide
For lamotrigine, avoid abrupt withdrawal (taper off over 2 weeks or longer) unless
serious skin reaction e.g. SJS, toxic epidermal necrolysis.
this AED is associated with acute myopia (near sightedness) with secondary CAG. usually happens within first month of starting
topiramate
which AEDS have MHRA advice because they can cause severe respiratory depression
pregabalin
gabapentin
the following AEDs can reduce vitamin D absorption by inducing CYP enzyme/increasing metabolism of vitamin D. therefore may need vit D supplementation
phenytoin, phenobarbital, carbamazepine, primidone, oxcarbamazepine
SV